Patrick Lamy

Senior VP, Commercial Strategy

Patrick Lamy (Senior VP, Commercial Strategy) filed 5 Form 4 reports in the past 24 months (0 purchases, 5 sales), most often in AKRO. The largest single filing was $340K of AKRO (8,000 sh across 2 lots, as filed), executed May 7 2025. Data as of Nov 8 2026.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 5 sells

Median delay

–

measured on stock purchases

Volume, ttmiDollar value disclosed in the trailing twelve months

$1.1M

shares × price, as filed

Last traded

Jul 1 2025

Filed Jul 3 2025

Open performance→

Volume by month

Buys $0 Sells $1.1M

Shares × price, as filed · by filing month · past 24 months

Most traded names

AKRO AKRO 0 buys · 5 sells 5 filings

Recent filings

AKROSALE Akero Therapeutics, Inc. View filing → $106K
2,000 sh × $52.88
Exec Jul 1 2025
Filed Jul 3 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $167K
3,300 sh × $50.46
Exec Jun 2 2025
Filed Jun 4 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $200K
4,000 sh × $50.00
Exec May 22 2025
Filed May 23 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $340K
8,000 sh across 2 lots
Exec May 7 2025
Filed May 9 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $285K
5,000 sh × $57.03
Exec Jan 27 2025
Filed Jan 29 2025 · 5:30 PM ET